$Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)$

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)

Summary Idelalisib (idela), a phosphatidylinositol 3‐kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R‐idel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2023-07, Vol.202 (1), p.40-47
Hauptverfasser:	Špaček, Martin, Smolej, Lukáš, Šimkovič, Martin, Nekvindová, Lucie, Křístková, Zlatuše, Brychtová, Yvona, Panovská, Anna, Mašlejová, Stanislava, Bezděková, Lucie, Écsiová, Dominika, Vodárek, Pavel, Zuchnická, Jana, Mihályová, Jana, Urbanová, Renata, Turcsányi, Peter, Lysák, Daniel, Novák, Jan, Brejcha, Martin, Líkařová, Tereza, Vodička, Prokop, Baranová, Jana, Trněný, Marek, Doubek, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged chronic lymphocytic leukaemia Chronic lymphocytic leukemia Clinical trials Enzyme inhibitors Hematology Humans ibrutinib idelalisib Karyotypes Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Multivariate analysis p53 Protein Protein-tyrosine kinase real‐world evidence Recurrence Registries Retrospective Studies Rituximab Survival Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!